Sign In
Buy GBIO
$5.34
+0 (+0%)
At Close: May 05, 2026
Generation Bio to Present at the 2022 Wedbush PacGrow Healthcare Conference
04:15pm, Tuesday, 02'nd Aug 2022
CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announce
Wall Street Analysts See a 174% Upside in Generation Bio Co. (GBIO): Can the Stock Really Move This High?
11:36am, Monday, 11'th Jul 2022
The average of price targets set by Wall Street analysts indicates a potential upside of 173.7% in Generation Bio Co. (GBIO). While the effectiveness of this highly sought-after metric is questionable
Generation Bio to Present at the 2022 Jefferies Healthcare Conference
07:30am, Thursday, 02'nd Jun 2022
CAMBRIDGE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announce
Generation Bio Co. (GBIO) Reports Q1 Loss, Lags Revenue Estimates
11:05pm, Thursday, 05'th May 2022 Zacks Investment Research
Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -17.31% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Generation Bio Reports Business Highlights and First Quarter 2022 Financial Results
08:15pm, Thursday, 05'th May 2022 GlobeNewswire Inc.
Company continues to optimize cell-targeted lipid nanoparticle (ctLNP) delivery system for nonviral genetic medicine applications in liver, retina and vaccines
Generation Bio to Participate in 21st Annual Needham Virtual Healthcare Conference
11:30am, Tuesday, 05'th Apr 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, annou
Generation Bio Co. (GBIO) Upgraded to Buy: Here's Why
04:00pm, Friday, 25'th Mar 2022 Zacks Investment Research
Generation Bio Co. (GBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
How Much Upside is Left in Generation Bio Co. (GBIO)? Wall Street Analysts Think 505%
02:00pm, Friday, 25'th Mar 2022 Zacks Investment Research
The consensus price target hints at a 504.9% upside potential for Generation Bio Co. (GBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin
Generation Bio to Participate in 42nd Annual Cowen Health Care Conference
12:30pm, Wednesday, 02'nd Mar 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, annou
Generation Bio to Participate in 42nd Annual Cowen Health Care Conference
12:30pm, Wednesday, 02'nd Mar 2022 GlobeNewswire
CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in the Gene Therapy panel discussion at the 42 nd Annual Cowen Health Care Conference on Wednesday, March 9 at 12:50 p.m. ET.
Generation Bio GAAP EPS of -$0.54 beats by $0.03
10:10pm, Thursday, 24'th Feb 2022 Seeking Alpha
Generation Bio press release (GBIO): Q4 GAAP EPS of -$0.54 beats by $0.03.Cash and cash equivalents were $375.1M as of December 31, 2021
Generation Bio Outlines 2022 Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results
09:20pm, Thursday, 24'th Feb 2022 GlobeNewswire Inc.
Well-capitalized with $375.1 million at the end of 2021, funding planned operations into 2024 Well-capitalized with $375.1 million at the end of 2021, funding planned operations into 2024
Generation Bio Outlines 2022 Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results
09:20pm, Thursday, 24'th Feb 2022 GlobeNewswire
Well-capitalized with $375.1 million at the end of 2021, funding planned operations into 2024 Well-capitalized with $375.1 million at the end of 2021, funding planned operations into 2024
Generation Bio promotes Paone to COO (NASDAQ:GBIO)
12:56pm, Thursday, 10'th Feb 2022 Seeking Alpha
Generation Bio (GBIO) announced Thursday the promotion of Antoinette Paone to chief operating officer. Paone has served as senior vice president and head of regulatory affairs and…
